|Systematic (IUPAC) name|
|Trade names||Faverin, Fevarin, Floxyfral, Luvox|
|Bioavailability||53% (90% confidence interval: 44-62%)|
|Metabolism||Hepatic (via cytochrome P450 enzymes. Mostly via oxidative demethylation)|
|Biological half-life||12-13 hours (single dose), 22 hours (repeated dosing)|
|Excretion||Renal (98%; 94% as metabolites, 4% as unchanged drug)|
|CAS Registry Number||Y|
|N (what is this?)|
Fluvoxamine (brand names: Faverin, Fevarin, Floxyfral, and Luvox) is a medication which functions as a selective serotonin reuptake inhibitor (SSRI) and σ1 receptor agonist. Fluvoxamine is used primarily for the treatment of obsessive-compulsive disorder (OCD), and is also used to treat major depressive disorder (MDD), and anxiety disorders such as panic disorder and post-traumatic stress disorder (PTSD). Fluvoxamine CR (controlled release) is approved to treat social anxiety disorder.
The FDA has added a black box warning for this drug in reference to increased risks of suicidal thinking and behavior in young adults and children.
Fluvoxamine's only FDA approved indication is in the treatment of OCD, although in other countries (e.g. Australia, UK and Russian Federation) it has indications for MDD, as well. Fluvoxamine has been found to be useful in the treatment of MDD, and anxiety disorders such as panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and obsessive-compulsive spectrum disorders. Fluvoxamine is indicated for children and adolescents with OCD. The drug works long-term, and retains its therapeutic efficacy for at least a year. It has also been found to possess some analgesic properties in line with other SSRIs and tricyclic antidepressants.
Some evidence shows fluvoxamine may be a helpful adjunct in the treatment of schizophrenia, improving the depressive, negative, and cognitive symptoms of the disorder. Its actions at the sigma receptor may afford it a unique advantage among antidepressants in treating the cognitive symptoms of schizophrenia.
Gastrointestinal side effects are more common in those receiving fluvoxamine than with other SSRIs. Otherwise, fluvoxamine's side-effect profile is very similar to other SSRIs.
Fluvoxamine inhibits the following cytochrome P450 enzymes:
By so doing, fluvoxamine can increase serum concentration of the substrates of these enzymes.
Fluvoxamine is a potent and selective serotonin reuptake inhibitor with around 100-fold affinity for the serotonin transporter over the norepinephrine transporter. It has negligible affinity for the dopamine transporter or any other receptor, with the sole exception of the σ1 receptor. It behaves as a potent agonist at this receptor and has the highest affinity of any SSRI for doing so. This may contribute to its antidepressant and anxiolytic effects and may also afford it some efficacy in treating the cognitive symptoms of depression.
Fluvoxamine was developed by Kali-Duphar, part of Solvay Pharmaceuticals, Belgium, now Abbott Laboratories, and introduced as Floxyfral in Switzerland and Solvay in West Germany in 1983. It was approved by the FDA on 5 Dec, 1994 and introduced as Luvox in the US. In India, it is available, among several other brands, as Uvox by Abbott. It was one of the first SSRI antidepressants to be launched, and is prescribed in many countries to patients with major depression. It was the first SSRI, a nonTCA drug, approved by the U.S. FDA specifically for the treatment of OCD. At the end of 1995, more than ten million patients worldwide had been treated with fluvoxamine. Fluvoxamine was the first SSRI to be registered for the treatment of obsessive compulsive disorder in children by the FDA in 1997. In Japan, fluvoxamine was the first SSRI to be approved for the treatment of depression in 1999 and was later in 2005 the first drug to be approved for the treatment of social anxiety disorder. Fluvoxamine was the first SSRI approved for clinical use in the United Kingdom.
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
生合成 トリプトファン → 5-ヒドロキシトリプトファン トリプトファン5-モノオキシゲナーゼ OH ／＼ ／＼／ -OOC-CH(NH3+)-CH2----|○｜ → -OOC-CH(NH3+)-CH2----| ○| || | | || | ｜ ＼ ／ ＼／ ＼ ／ ＼／ NH NH + + テトラヒドロビオプテリン ジヒドロビオプテリン + O2 5-ヒドロキシトリプトファン → セロトニン 芳香族アミノ酸デカルボキシラーゼ OH ／＼ ／＼／ -OOC-CH(NH3+)-CH2----|○ | → H2N-CH2-CH2----| ○| || | ｜ || | | ＼ ／ ＼／ ＼ ／＼／ NH NH